B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Alec Stranahan maintains a Buy rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $48 to $55.
July 16, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities analyst Alec Stranahan maintains a Buy rating on Revolution Medicines and raises the price target from $48 to $55.
The Buy rating and increased price target from a reputable analyst at B of A Securities is likely to boost investor confidence in Revolution Medicines, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100